International Council for Standardization in Haematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls

Abstract

The clinical laboratory uses commercial products with limited shelf life or certain expiry dates requiring frequent lot changes. Prior to implementation for clinical use, laboratories should determine the performance of the new reagent lot to ensure that there is no significant shift in reagent performance or reporting of patient data. This guideline has been written on behalf of the International Council for Standardization in Haematology (ICSH) to provide the framework and provisional guidance for clinical laboratories for evaluating and verifying the performance of new lot reagents used for coagulation testing. These ICSH Working Party consensus recommendations are based on good laboratory practice, regulatory recommendations, evidence emerged from scientific publications, and expert opinion and are meant to supplement regional standards, regulations, or requirements.

Keywords

new lot reagent verification - coagulation testing - laboratory

Publikationsverlauf

Artikel online veröffentlicht:
15. November 2023

• References

• 1 CLSI. User Evaluation of Acceptability of a Reagent Lot Change. 2nd ed.. CLSI Guideline EP26. Clinical and Laboratory Standards Institute; 2022
• 2 International Organization for Standardization. Medical Laboratories—Requirements for Quality and Competence (ISO Standard Number 15189:2022). Geneva, Switzerland:
• 3 International Organization for Standardization. In Vitro Diagnostic Medical Devices—Measurement Of Quantities in Samples of Biological Origin—Requirements for Content and Presentation of Reference Measurement Procedures (ISO standard number 15193:2009). Geneva, Switzerland:
• 4 United States Department of Health and Human Services. Food and Drug Administration. Bioanalytical Method Validation; Guidance for Industry. May 2018. Accessed September 18, 2021 at: https://www.fda.gov/media/70858/download
• 5 United States Code of Federal Regulations (CFR). Title 42, Chapter IV, Subchapter G, part 493 Laboratory Requirements. Accessed September 18, 2021 at: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493
• 6 College of American Pathologists (CAP) All Common Checklist. COM.30450: New Reagent Lot Confirmation of Acceptability that New Lot Reagents, 2020. Northfield, IL:
• 7 Favaloro EJ, Gosselin RC, Pasalic L, Lippi G. Hemostasis and thrombosis: an overview focusing on associated laboratory testing to diagnose and help manage related disorders. Methods Mol Biol 2023; 2663: 3-38
• 8 Gardiner C, Coleman R, de Maat MPM. et al. International Council for Standardization in Haematology (ICSH) laboratory guidance for the evaluation of haemostasis analyser-reagent test systems. Part 1: instrument-specific issues and commonly used coagulation screening tests. Int J Lab Hematol 2021; 43 (02) 169-183
• 9 Gardiner C, Coleman R, de Maat MPM. et al. International Council for Standardization in Haematology (ICSH) laboratory guidance for the verification of haemostasis analyser-reagent test systems. Part 2: specialist tests and calibrated assays. Int J Lab Hematol 2021; 43 (05) 907-916
• 10 Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 2017; 43 (03) 253-260
• 11 Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49 (03) 238-244
• 12 Tripodi A, Chantarangkul V, Mannucci PM. The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. J Thromb Haemost 2008; 6 (02) 243-248
• 13 Adcock D. et al. Validation of INR and local calibration of PT INR systems. Approved guideline. CLSI document H54-A. Clinical and Laboratory Standards Institute; 2005
• 14 Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy with vitamin K antagonists Replacement of Annex 3 of WHO Technical Report Series, No. 889 Annex 6. World Health Organization (WHO); 2013. . Accessed May 26, 2023 at: https://cdn.who.int/media/docs/default-source/biologicals/blood-products/document-migration/trs_979_annex_6.pdf?sfvrsn=5c960b91_3&download=true
• 15 Favaloro EJ, Hamdam S, McDonald J, McVicker W, Ule V. Time to think outside the box? Prothrombin time, international normalised ratio, International Sensitivity Index, mean normal prothrombin time and measurement of uncertainty: a novel approach to standardisation. Pathology 2008; 40 (03) 277-287
• 16 Favaloro EJ, McVicker W, Zhang Y. et al. Improving the inter-laboratory harmonization of the international normalized ratio (INR): utilizing the concept of transference to estimate and/or validate International Sensitivity Index (ISI) and mean normal prothrombin time (MNPT) values and/or to eliminate measurement bias. Clin Lab Sci 2012; 25 (01) 13-25
• 17 Favaloro EJ. Optimizing the verification of mean normal prothrombin time (MNPT) and International Sensitivity Index (ISI) for accurate conversion of prothrombin time (PT) to international normalized ratio (INR). Methods Mol Biol 2017; 1646: 59-74
• 18 Favaloro EJ. How to generate a more accurate laboratory-based international normalized ratio: solutions to obtaining or verifying the mean normal prothrombin time and international sensitivity index. Semin Thromb Hemost 2019; 45 (01) 10-21
• 19 Gosselin RC, Adcock DM, Bates SM. et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
• 20 CLSI. Defining, establishing, and verifying reference intervals in the clinical laboratory. Approved guideline. CLSI document C29–A3c. Clinical and Laboratory Standards Institute; 2005
• 21 CLSI. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays—Sixth Edition. CLSI document H21. Clinical and Laboratory Standards Institute; 2022
• 22 Bilić-Zulle L. Comparison of methods: Passing and Bablok regression. Biochem Med (Zagreb) 2011; 21 (01) 49-52
• 23 Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin inhibitors. Semin Thromb Hemost 2017; 43 (03) 270-276
• 24 Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost 2019; 45 (01) 22-35
• 25 Do L, Favaloro E, Pasalic L. An analysis of the sensitivity of the activated partial thromboplastin time (APTT) assay, as used in a large laboratory network, to coagulation factor deficiencies. Am J Clin Pathol 2022; 158 (01) 132-141
• 26 CLSI. One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline—Second Edition. CLSI document H47-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008
• 27 Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119 (02) 104-109
• 28 Undas A. Determination of fibrinogen and thrombin time (TT). Methods Mol Biol 2017; 1646: 105-110
• 29 CLSI. Determination of Coagulation Factor Activities Using the One-Stage Clotting Assay CLSI document H48 2nd Edition. Clinical and Laboratory Standards Institute; 2016
• 30 Adcock DM, Moore GW, Montalvão SL, Kershaw G, Gosselin RC. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art. Semin Thromb Hemost 2023; 49 (06) 571-579
• 31 CLSI. Laboratory testing for the lupus anticoagulant. Approved guideline. H60-A Wayne, PA: Clinical and Laboratory Standards Institute; 2014
• 32 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11) 2828-2839
• 33 Aringer M, Costenbader K, Daikh D. et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019; 71 (09) 1400-1412
• 34 Hayward CP, Moffat KA, Raby A. et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134 (06) 955-963
• 35 Mammen EF, Comp PC, Gosselin R. et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24 (02) 195-202
• 36 Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag 2015; 11: 133-148
• 37 CLSI. Platelet Function Testing by Aggregometry. Approved guideline. CLSI document H58-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2008
• 38 Platton S, McCormick Á, Bukht M, Gurney D, Holding I, Moore GW. A multicenter study to evaluate automated platelet aggregometry on Sysmex CS-series coagulation analyzers-preliminary findings. Res Pract Thromb Haemost 2018; 2 (04) 778-789
• 39 Carll T, Wool GD. Basic principles of viscoelastic testing. Transfusion 2020; 60 (Suppl. 06) S1-S9
• 40 Volod O, Runge A. Measurement of blood viscoelasticity using thromboelastography. Methods Mol Biol 2023; 2663: 709-724
• 41 Hoeltge GA. Accreditation of individualized quality control plans by the College of American Pathologists. Clin Lab Med 2017; 37 (01) 151-162
• 42 Perry DJ, Fitzmaurice DA, Kitchen S, Mackie IJ, Mallett S. Point-of-care testing in haemostasis. Br J Haematol 2010; 150 (05) 501-514
• 43 Riley RS, Gilbert AR, Dalton JB, Pai S, McPherson RA. Widely used types and clinical applications of D-Dimer assay. Lab Med 2016; 47 (02) 90-102
• 44 Fitzmaurice DA, Geersing GJ, Armoiry X, Machin S, Kitchen S, Mackie I. ICSH guidance for INR and D-dimer testing using point of care testing in primary care. Int J Lab Hematol 2023; 45 (03) 276-281
• 45 Miller WG, Erek A, Cunningham TD, Oladipo O, Scott MG, Johnson RE. Commutability limitations influence quality control results with different reagent lots. Clin Chem 2011; 57 (01) 76-83
• 46 Rimsans J, Douxfils J, Smythe MA. et al. Overview and practical application of coagulation assays in managing anticoagulation with direct oral anticoagulants (DOACs). Curr Pharmacol Rep 2020; 6: 241-259
• 47 Gray E, Kitchen S, Bowyer A. et al. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: a United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia 2020; 26 (01) 6-16
• 48 National Institute of Biological Standards and Controls (NIBSC). Biological Reference Materials, Haemostasis. London, United Kingdom. Accessed September 18, 2021 at: https://www.nibsc.org/products/brm_product_catalogue/sub_category_listing.aspx?category=Biotherapeutics&subcategory=Haemostasis